GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, has announced the results from the final analysis of the REALITY natural history study, which reaffirms the poor… Read More »GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit.
Clinical researchers based at the UCL Institute of Ophthalmology, University College London and Moorfields Eye Hospital, have published a new study that identifies how mobility… Read More »Clinical research on a new mobility assessment tool for RPE65-associated retinal dystrophy.
Family organisations and the Foundation Fighting Blindness have published a new report on an initiative outlining a model for how affected individuals and their families… Read More »A report on a workshop for accelerating the development of treatments for inherited retinal degenerations (IRDs).
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 7th, 2020 edition of EURETINA’s web-based digital… Read More »September 7th, 2020: “EURETINA-Brief”© Issue No. 220
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***